

# **HHS Public Access**

J Int Neuropsychol Soc. Author manuscript; available in PMC 2018 February 08.

Published in final edited form as:

Author manuscript

J Int Neuropsychol Soc. 2017 February ; 23(2): 159–170. doi:10.1017/S1355617716001132.

# Cognitive control, learning and clinical motor ratings are most highly associated with basal ganglia brain volumes in the premanifest Huntington's disease phenotype

M.B. Misiura<sup>1</sup>, S. Lourens<sup>2</sup>, V. D. Calhoun<sup>3,4</sup>, J. Long<sup>2</sup>, J. Bockholt<sup>2</sup>, H. Johnson<sup>2</sup>, Y. Zhang<sup>2</sup>, J.S Paulsen<sup>2,\*</sup>, J.A. Turner<sup>1,\*</sup>, and PREDICT-HD Investigators & working group <sup>1</sup>Department of Psychology, Georgia State University

<sup>2</sup>University of Iowa Carver College of Medicine

<sup>3</sup>The Mind Research Network

<sup>4</sup>Department of Electrical and Computer Engineering, The University of New Mexico

### Abstract

**Objective**—Huntington's Disease (HD) is a debilitating genetic disorder characterized by motor, cognitive and psychiatric abnormalities associated with neuropathological decline. HD pathology is the result of an extended chain of CAG (cytosine, adenine, guanine) trinucleotide repetitions in the *HTT* gene. Clinical diagnosis of HD requires the presence of an otherwise unexplained extrapyramidal movement disorder in a participant at risk for HD. Over the past 15 years, evidence has shown that cognitive, psychiatric, and subtle motor dysfunction is evident decades before traditional motor diagnosis. This study examines the relationships among subcortical brain volumes and measures of emerging disease phenotype in prodromal HD, prior to clinical diagnosis.

**Method**—The dataset includes 34 cognitive, motor, psychiatric, and functional variables and five subcortical brain volumes from 984 prodromal HD individuals enrolled in the PREDICT HD study. Using cluster analyses, seven distinct clusters encompassing cognitive, motor, psychiatric, and functional domains were identified. Individual cluster scores were then regressed against the subcortical brain volumetric measurements.

**Results**—Accounting for site and genetic burden (the interaction of age and CAG repeat length) smaller caudate and putamen volumes were related to clusters reflecting motor symptom severity, cognitive control and verbal learning.

**Conclusion**—Variable reduction of the HD phenotype using cluster analysis revealed biologically related domains of HD and are suitable for future research with this population. Our cognitive control cluster scores show sensitivity to changes in basal ganglia both within and outside the striatum that may not be captured by examining only motor scores.

<sup>\*</sup>Senior Authors. jane-paulsen@uiowa.edu and jturner@mrn.org, Address: 305 Medical Education Building, 200 Newton Road, Iowa City, IA 52242

### Keywords

Basal Ganglia; Striatum; Prodromal Huntington's Disease; Caudate; Clustering; Cluster Analysis; Neuropsychology; Cognition; Psychiatric symptoms; Cognitive control

### Introduction

Huntington's disease (HD) is a fatal neurological disorder characterized by involuntary movements, impairment of voluntary movement, elevated psychiatric abnormalities, and cognitive decline. Caused by a mutation of expanded trinucleotide cytosine, adenine, guanine (CAG) repeats in the autosomal dominant Huntingtin gene (*HTT*), this debilitating disease affects 12.3 to 17.2 people per 100,000 in the Western world (Evans et al., 2013; Fisher & Hayden, 2014). Clinical diagnosis requires the presence of an otherwise unexplained movement disorder in a participant at risk for HD. Since the 2001 Huntington Study Group publication showing that marked cognitive impairment predicted the prospective diagnoses of 70 out of 260 at-risk individuals, the field witnessed an explosion of publications showing cognitive, psychiatric and motor dysfunction in persons at-risk for HD (Paulsen et al., 2006; Paulsen et al., 2001, 2008a, 2014). Recently, an issue of the Movement Disorder Society journal described "stages" of HD before diagnosis (Reilmann, et. al, 2014).

Premanifest HD means the individual has undergone testing and has CAG mutation but has no symptoms or signs. Prodromal HD means the individual has undergone testing, has CAG mutation and has symptoms or signs but does not meet motor criteria for diagnosis. While it is still unknown what brain dysfunction contributes to the length of time an individual stays in premanifest or prodromal phases of this disease before obtaining a clinical diagnosis, there are distinct changes that occur during this time. The purpose of this study is to determine which subcortical grey matter volumes relate to measures of the the HD phenotype including measures of cognitive, motor, psychiatric, and functional manifestations.

The PREDICT-HD study is a longitudinal study of over 1100 premanifest and prHD participants, or those individuals who had predictive testing and have the HD gene mutation (prHD) but no diagnosis (Paulsen et al., 2006; Paulsen et al., 2008a, Paulsen et. al. 2014). Designed to provide a more definite time window of disease manifestation, the PREDICT-HD study tracks premanifest and prHD participants and evaluates biological and clinical changes (Paulsen et al., 2008b). A variety of studies using the PREDICT-HD dataset identified cognitive, motor, psychiatric, and functional changes within this population before motor diagnosis. This study builds on the previous work of the PREDICT-HD group by analyzing a comprehensive set of cognitive, motor, psychiatric, and functional measures and characterizing their associations with brain volumes associated with HD pathology.

There is still not a consensus about which measures best relate to the underlying neuropathology of the premanifest stages of HD. The goal of this study is to determine which domains are most highly associated with subcortical basal ganglia (BG) volumes.

These relationships may help elucidate changes in phenotype and symptom severity in the premanifest and prodromal populations.

#### Clinical profile of prodromal HD

PrHD individuals often exhibit deficits in executive function tasks, including those involving cognitive control, working memory (Harrington et al., 2012; Snowden, et. al., 2002; Stout et al., 2011; Williams et al., 2015). Across studies involving prodromal HD (prHD), participants perform significantly worse than controls on a wide variety of tasks. In one publication from the large PREDICT-HD study involving over 900 prHD (Stout et al., 2011), findings shows that controls outperformed prHD individuals in 16 out of 19 cognitive tasks. A longitudinal analysis of PREDICT-HD data, detected a decline in performance in many cognitive domains were detected. There is widespread evidence that prHD individuals exhibit cognitive deficits, and that these deficits increase over time. However, exactly which specific measurements of the HD phenotype best track disease progression in relation to brain changes has not yet been established.

Harrington et. al. (2012) conducted a factor analysis on a targeted subset of the neuropsychological measures from the PREDICT-HD study, and found that a factor structure involving speed and inhibition, verbal working memory, motor planning and speed, attention and information integration, sensory and perceptual processing, and verbal learning and memory best form distinct factors within these data. Findings suggested that cognitive domains related to motor planning and sensory-perceptual processing most strongly predicted time to diagnosis, after taking into account age, the number of CAG repeats, and motor symptom severity. These results have not been analyzed in combination with brain volumes in a prHD population. While we anticipate that we will find similar cognitive factors within this analysis of the larger phenotypic dataset, for this study we build upon previous findings by including the subcortical brain volumes and analyzing a larger set of clinical measures that encompasses a wider range of disease manifestation. We chose to employ a clustering analysis on a superset of clinical variables (including all three primary components of HD: cognitive, motor and psychiatric severity) as well as functional capacity. The benefit of the cluster analysis is that it enables us to utilize all clinical domains in our study. The Harrington analysis only used cognitive factors to predict time to diagnosis, but we wanted to examine how all HD clinical domains related to subcortical brain volumes.

Psychiatric symptoms are typically elevated in premanifest individuals relative to controls. Publications emphasize depression, obsessive-compulsive symptoms, and apathy in most of the research investigating the psychiatric phenotype of HD. Depression is a common symptom in prHD, and has been documented at a prevalence rate as high as 59%, and depressive symptoms can increase with time to onset (Epping et al., 2013; Julien et al., 2007; Naarding, Joost, Janzing, Eling, van der Werf, & Kremer, 2009; Vaccarino et al., 2011). Individuals in the premanifest and prodromal phases of HD are 15–88 times more likely to experience apathy, than gene-negative individuals, and some report prevalence rates as high as 62% (Duff et al., 2007; Martinez-Horta et al., 2016). Apathy is commonly present in the absence of other depressive symptoms in other movement disorders (Duff et al., 2007; Levy et al., 1998; Litvan, et. al, 1998; Naarding, et. al, 2009). Irritability, aggression, and

obsessive compulsive behaviors are also elevated in HD (Beglinger et all., 2008; Epping et al., 2015; Julien et al., 2007; Kloppel et al., 2009). Many individuals involved in these studies know they will eventually develop HD, and this many account for some of the elevated psychiatric symptoms, as this can put an enormous amount of psychological stress on affected individuals. However, because some psychiatric symptoms increase as time to diagnosis decreases, it may be that brain correlates related to disease progression underlie psychiatric symptoms (Marin, 1991; Pla, et. al, 2014).

#### Imaging profile of prHD

Multiple morphological and structural changes are detectable in individuals with expanded CAG repeats well before clinical diagnosis. Atrophy in the striatum is the most consistently reported imaging sign of early HD, and is the most common finding across prHD studies, including PREDICT-HD and TRACK-HD (Aylward et al., 2011; Halliday et al., 1998; van den Bogaard et al., 2011; Wolf et al., 2013). Structural abnormalities in regions of th accumbens and pallidum often show correlations with clinical variables, but findings are not consistent across studies. Nearly all studies identified neuropsychological and psychiatric variables that relate to brain volumes, but exactly which measures relate to brain volumes is not consistent. This study uses variable reduction to consider these relationships using a large sample in an effort to replicate and possibly clarify mixed findings.

Multiple studies identified the caudate and putamen as areas highly sensitive to CAG expansion, and related to cognitive function (Aylward et al., 2011; Jech et al., 2007; Paulsen et al., 2010; Tabrizi et al., 2011). Within the prHD population, BG volumes are often related to a variety of clinical measures including tests of disinhibition, speed, attention, working memory, planning and problem-solving, organization, learning and motor symptoms (Aylward et al., 2013; Harrington et al., 2014). In a large study with PREDICT-HD data, both putamen and caudate volumes were associated with performances on the Symbol Digit Modalities Test (SDMT), an emotion recognition test, and a task requiring internal timing (Harrington et al., 2014). Using cluster analyses, we anticipate similar relationships using aggregated measures of cognition, as well as psychiatric symptoms, motor abnormalities and functional capacity with BG volumes.

We anticipate a negative relationship between motor scores and imaging measures of the BG (i.e., caudate, putamen, and globus pallidus volumes). Better performances on some tests of cognition should be related to greater putamen, caudate, and globus pallidus volumes as reported in similar studies. Additionally, we anticipate that the more severe psychiatric symptoms will be associated with nucleus accumbens volume.

### Methods

### Participants

For this study, we used all prodromal HD individuals in the PREDICT-HD study (Paulsen et al., 2014) who had imaging measures collected at the same time as clinical measures. Individuals without the *HTT* expansion were not included. This study was approved at each site where data was collected, and all data was shared in accordance with the University of

Iowa and Georgia State University Institutional Review Boards. The number of CAG repeats in the mutant *HTT* gene was determined from a blood sample for each participant. Any individual with a CAG repeat length greater than 35 is considered premanifest (Walker, 2007), and only these individuals were considered for this analysis.

Because age has a differential effect on predicted time to diagnosis across different levels of CAG repeat lengths, we chose to employ a derived variable, the CAG by Age Product (CAP score), where  $CAP = age \times (CAG - 33.66)$  (Zhang et al., 2011). For this cross-sectional analysis, we analyzed the first time point from each participant that included both a T1-weighted structural magnetic resonance image (MRI) of sufficient quality for subcortical segmentation, and the full battery of cognitive, motor, psychiatric, and functional measures at the same time the scans were collected. CAP was calculated based on age at the time of data collection.

Participants include 984 prodromal HD individuals (Mean age=41.87, SD= 11.08). Our sample contained 684 females, and 324 males. Although this gender imbalance is not representative of the HD population, it is consistent with other premanifest studies such as TRACK, COHORT, and PHAROS. Nevertheless, we controlled for gender in all of our models to ensure that the effects identified were not driven by an unequal gender distribution. Demographic information for the HD phenotype cluster analysis is displayed in Table 1. We used data from the same pool of participants for both the cluster and the regression analyses.

### **Clinical Variables**

The PREDICT-HD data set includes 34 measures of clinical phenotype, including performance-based neuropsychological assessments, clinician-reported motor ratings, selfand companion-reported psychiatric ratings, and self- and companion-reported functional capacity, listed in Figure 1 and Appendix 1. A short description of the measures is included in the supplementary material. Not all individuals had complete data. Each assessment's values were z-scored across all available premanifest HD participants prior to statistical analyses.

#### **Cluster analysis**

We performed a hierarchical cluster analysis using the hclust package in R on the z-scored clinical measures. The median number of pairwise complete observations was 803 with a range of 702 to 984. To perform a hierarchical cluster analysis, a dissimilarity matrix is constructed based on the distance between two variables defined as (1-abs (Spearman's rank correlation)). Ward's minimum variance method (Ward, 1963) was applied which merges clusters based on the optimal value at each step. We chose an inconsistency value of 1 as shown in Figure 1, that divided the measures into specific clusters encompassing specific phenotypic domains which we labeled as: perception, learning/memory, and language; cognitive control; problem solving; tapping; motor ratings; function; and psychiatric symptoms.

Average cluster scores for each participant were computed based on their scores for each measure in the cluster. That is, each of their z-scored values from each measure in the cluster

Page 6

was summed and averaged. To maintain consistency in our interpretation, a higher numerical score for a cluster indicated higher functioning, greater levels of clinical distress, better cognitive performances, or more severe motor symptoms. Only individuals who had all the measures from each cluster received a score for that cluster

As shown in Figure 1, using 1.0 as the cut-off the data clustered into seven clinical phenotype domains for HD which we labeled (1) Psychiatric, (2) Function, (3) Motor, (4) Tapping, (5) Problem-solving, (6) Cognitive control, and (7) Perception, Learning/Memory, and Language. The findings show that the data first divided into two large clusters at 2.0 separating Psychiatric from all other measures. The second division occurred at 1.5 separating Motor ratings and Function from all other measures. The third division separated the Tapping measures from all other cognitive performance-based measures and the fourth division partitioned the Problem-solving from the remaining cognitive outcomes. The final separation that is above the 1.0 cut-off is the separation of the Stroop Color Word test, SDMT, and the Trail Making Test (Cognitive Control) from the remaining eight cognitive measures. The next two clusters that may have occurred and are relatively close to the cut-off score would separate components of the motor exam (chorea/oculo/brady vs. rigid/ dystonia) and would separate sensory/perceptual outcomes from the remaining cognitive scores..

#### Scanning parameters

High resolution anatomical MR images were collected at 32 collection sites using General Electric, Phillips, and Siemens scanners with field strengths of 1.5T or 3T (Tesla), using standard acquisition parameters. T1 images at each site were obtained using three-dimensional (3D) T1-weighted inversion recovery turboflash (MP-RAGE) sequences. Parameters for the 3T scans were similar to the following: GRAPPA factor, 900ms TI (inversion time), 2530ms TR, 3.09ms TE, 256×256mm Field of View (FoV), 10° flip angle, 2,240 coronal slices with 1mm slice thickness, 256×128 matrix with 1/4 phase FoV, 220 Hz/ pixel receiver bandwidth.

The protocol for 1.5T scanners commonly involved a sagittal localizing series followed by acquisition of an axial 3D volumetric spoiled GRASS (Gradient Recalled Acquisition in Steady State) sequence, using the following scan parameters: ~1×1×1.5mm voxel size, 18ms TR (relaxation time), 3ms TE (excitation time), 24cm FoV (field of view), 20° flip angle, 124 slices with 1.5mm slice thickness, 0mm gap, 256×192 matrix with 3/4 phase FoV, NEX (number of excitations) of two. Images were aligned with the AC-PC (anterior cingulate-posterior cingulate) plane (Ghayoor, Vaidya, & Johnson, 2013) and resampled with 1mm isotropic voxels to correct for inhomogeneity (Kim, et. al, 2014).

#### **Brain volumes**

Individuals considered for this analysis had both T1 weighted images that were compatible for the BRAINSTools algorithm, and had undergone the full battery of motor, cognitive, psychiatric and functional measures. From the structural T1 images, we extracted 16 brain volume measures using the BRAINSTools algorithm (Kim et al., 2014; Young Kim & Johnson, 2013). This analysis focuses on the subcortical volumetric measurements of the

thalamus and components of the BG that include caudate, putamen, nucleus accumbens, and globus pallidus. In order to control for total intracranial volume (ICV), we calculated each brain volume as a percentage of ICV.

### **Statistical analyses**

To be able to compare which brain volumes were the most strongly related to each cluster score, we analyzed our five subcortical measures in one model for each cluster score. Linear mixed models (LMMs; Verbeke & Molenberghs, 2000) were used to model the data. Various scanner strengths and types of scanners can image the brain differently, which is why it is crucial to model the site effects (Fennema-Notestine et al., 2007; Jovicich et al., 2009; Moorhead et al., 2009). We modeled scanner site as a random effect, and all other variables were modeled as covariates. The outcome variables for the regression models were the cluster scores; the covariates were CAP score (which includes age), gender, years of education, and the independent variables of interest were five individual brain volume measurements (caudate, putamen, globus pallidus, nucleus accumbens, and thalamus).

Individuals who did not have all measures for a specific cluster score were not used in that specific cluster model, but may contribute to a different cluster score for which they had all measures. For example, if an individual did not have a score for the Stroop Color Word Test, he or she would not be included in the regression model for the Cognitive Control cluster, but if this individual had all blocks from the tapping tasks completed, their data would be used in the Tapping cluster regression model. This approach generated varying numbers of individuals within each model, and each model has its own number of participants, listed following the model results.

Because of the heterogeneity of the Perception, Learning/Memory, and Language, cluster, we conducted a post-hoc analysis in which we used individual cluster scores for the highest three subclusters: Learning/Memory (2 measures from the HVLT), Sensory-Perceptual identification (facial and smell recognition), and the remaining measures which included dual verbal working memory, letter number sequencing, negative emotion recognition, ANART, and verbal fluency (i.e., Language cluster).

### Results

We reported full model statistics only for cluster scores that significantly related to brain volumes including estimates of the fixed effects, *t* scores and *p* values associated with independent variables of interest. All reported p-values have been corrected using False Discovery Rate correction in the "R stats" package (R, 2015) Full model statistics of all other cluster score results can be found in the supplementary material. As anticipated, years of education, gender, and CAP score were related to many of our cluster scores. Coefficient statistics for those variables are reported in the supplementary material along with a table of the results from each model. Reporting only significant findings, here we report on associations between brain imaging volumes with the Motor and Cognitive Control clusters and the post-hoc findings of brain imaging volumes with the Learning/Memory and Language subclusters.

#### Motor Symptoms

Caudate volumes (B=-1, t(936)=-2.74, p<.05) and putamen volumes (B=-1.07, t(936)=-2.36, p<.05) were both negatively related to motor symptoms. As ratings of motor symptom severity increases, caudate and putamen volumes decrease.

#### Cognitive control

Three subcortical volumes were significantly related to Cognitive Control cluster scores: putamen (B=1.31, t(904)= 2.59, p<.05), accumbens (B=1.22, t(904)= 2.52, p<.05), and globus pallidus (B=1.42, t(904)= 1.17, p<.05). As brain volumes decrease, Cognitive Control performances declined.

#### Learning/Memory subcluster analyses

The **Learning/Memory** subcluster was related to caudate volumes. As caudate volumes decrease, performance on the HVLT worsens (B=1.99, t(664)=3.07, p<.01).

### Discussion

Findings from this study illustrate a statistically-driven model of the progression of the HD clinical phenotype that is validated with strong associations of decreased volumes of the BG. Findings support previous work supporting that MRI volumes of caudate and putamen are the most robust and commonly cited regions of atrophy in prodromal HD (Paulsen et al., 2006; Paulsen et al., 2010; van den Bogaard et al., 2011). Furthermore, our findings show that additional BG atrophy is associated with measures of cognitive control, motor symptom severity, and verbal learning.

As hypothesized, striatum volumes significantly relate to motor symptom severity. The estimate of the putamen volume regression coefficient against motor symptom scores was not drastically different from that of the caudate, indicating that both volumes are relatively equally related to motor symptom scores. Even though this population does not show motor symptoms at a level that qualifies for full motor diagnosis, motor abnormalities are evident and significantly related to caudate and putamen volume loss.

It was surprising that we did not find significant relationships between motor speed performance based on measures of finger tapping and BG volumes. This could be a result of the combination of specific tapping tasks used to create the Tapping cluster score, although the tasks include those used by several other studies and papers. There is a difference between our approach to the tapping task and others' findings. Our goal was to utilize the most measures to determine whether cluster analyses could provide variable reduction for more stable measures for clinical trial assessment, other papers have used one or two tapping measures that showed the greatest effect sizes. The tapping tasks included here involve dominant finger tapping, non-dominant finger tapping and dual thumbs tapping. We also used all measures from the timed tapping task which requires subjects to keep pace with a metronome. Given the variety of tasks in this measure, the association with the rather large brain measures captured here may lacked sensitivity to document specific circuits for these motor tasks. Alternatively, while prodromal HD individuals do experience impaired

performance on both speeded and paced tapping tasks, it has been suggested that motor speed may be more related to metabolic functions within the striatum rather than directly related to volume loss (Joost, Raymund, Leenders, & Spikman, 2014). We recommend future research in movement disorders consider carefully the dissection of clinical outcome measures for motor components as has been successfully done in other papers (O'Rourke et al., 2011).

Some of our previous research also suggests that paced tapping may be impaired earlier than speeded tapping in prodromal HD which could also account for our findings, as these scores were both included in the tapping cluster scores (Paulsen, 2010).. These findings are highly consistent with others and efforts to better assess subtle aspects of motor abnormalities in premanifest and prodromal HD is of high importance for early HD detection and the future of preventive clinical trials in this disease. Our findings might be interpreted as arguments against using composite scores for HD clinical trials.

The Cognitive Control cluster scores were comprised of a variety of common tasks believed to measure an individual's ability to suppress an initial reaction to a stimulus, while retaining a sense of urgency, as they are timed assessments. Putamen, accumbens and globus pallidus volumes were significantly related to Cognitive Control cluster scores. These findings reflect others suggesting that these highly sensitive tasks may be critical for early detecton and tracking of HD in the premanifest stages. In the literature, these regions are also associated with cerebellar-frontal cortex loops that are responsible for exercising cognitive control (Dalley, Everitt, & Robbins, 2011; Leisman, Braun-Benjamin, & Melillo, 2014). Within the indirect and direct pathways of the BG, that modulate input from the frontal cortex to control motor movements, the striatum is the first region of the BG that receives input from various frontal regions (Alexander & Crutcher, 1990). From a cognitive perspective, the indirect pathway is important in suppressing unwanted behavior and the direct pathway selects the appropriate behavioral responses (Leisman et al., 2014). It follows that damage to the striatum in the form of atrophy would impact the cognitive selection processes that are crucial to cognitive control (Elliott, 2003).

Previous research suggests that the globus pallidus and the nucleus accumbens mediate the participation of the frontal executive areas during tasks of cognitive control, and that atrophy in this region may elicit poor performance on such tasks (Elliott, 2003). Additionally, the nucleus accumbens has a larger effect size than the other subcortical volumes, and this could be a result of the nucleus accumbens' involvement in apathy, a clinical symptom prevalent in this population (Marin, 1991; Naarding et al., 2009). Within HD and other subcortical diseases, increased apathy is related to decreased performance in tasks of cognitive control (Meyer et al., 2014; Vaccarino et al., 2011). Increased apathy or depressed mood as a result of caudate degeneration could also impact cognitive control although our Psychiatric cluster showed no significant findings with our MRI measures.

The caudate is an important site for the suppression of unwanted behavior, a crucial aspect of cognitive control (Elliott, 2003). Although we did anticipate that both caudate and putamen volumes would be related to cognitive control, our findings identified a significant relationship between putamen volumes and cognitive control cluster scores (Elliott, 2003;

Harrington et al., 2014; Unschuld et al., 2012). Although it could be the case that atrophy in the caudate does not explicitly affect performance on the measures used in our study, or that compensation by other brain regions mitigates a drop in performance (Malejko et al., 2014), we do not consider this an appropriate interpretation. Many other studies have identified caudate involvement in cognitive control tasks, including our own. We (and others) found that caudate measures are often less reliable than the putamen measure; it has been suggested that since the caudate is located by ventricles accurate volumes are more difficult to acquire (Whalley & Wardlaw, 2001). Additional recent research using connectivity measures are showing promise as a brain marker for impaired cognitive control (Harrington et al., 2015; Koenig et al., 2014).

We did not find significant relationships between brain volumes and the Perception, Learning/Memory, and Language cluster when analyzed as a whole. This may be a result of the fact that this cluster is comprised of more heterogeneous cognitive demands. It may also be a result of the fact that individuals in the prodromal and premanifest stages of HD have relatively intact premorbid intellect and do not yet exhibit impaired performance on many of the language-based tasks. This also may explain why some of the more executive control tasks in this cluster, such as verbal fluency or working memory, may not group together with other cognitive control tasks. Verbal performance is mostly spared in this population and has been used in the past as a method to separate so-called "subcortical" from traditionally "cortical" dementias. Since primary language and memory storage are not impacted by HD, it follows that these cognitive tasks failed to differentiate using cluster analyses. It has been shown that imaging findings in the premanifest stage suggest brain compensation from intact brain areas during performances traditionally dependent on the BG. It may be that the more intact perceptual, memory and language skills are providing assistance for language-based cognitive control tasks. It is encouraging to note that cluster analyses provided strong face validity for the clinical phenotype of HD and did not simply reflect clustering of normal brain functions.

Many of the measures in the language and memory subclusters as well as the cognitive control cluster were also included in the Harrington (2012) factor analysis. Although these measures were related to each other at the level of our hierarchical cut-point, the large number of variables may be too much of a conglomeration of constructs to be meaningful. To investigate this further, we broke down this cluster score into its subdivisions similar to those used in the Harrington (2012) factor analysis, as the cognitive variables in the factor analysis grouped together at the same level of similarity as in the factor analysis. Only the verbal learning subcluster was linked to any of the brain volumes of interest, which is consistent with previous literature (Harrington et al., 2014). As caudate volumes decrease, performance on verbal learning tasks decreases. For future studies involving brain volumes we will consider using this subcluster score.

Planning or problem-solving, as required by the towers task, may have less robust associations with the brain volumes of interest, and may be better analyzed in concert with functional or white matter measures. In previous research with this population, accuracy on the towers task decreased as striatum volumes decreased (Papp et al., 2013). However, this finding was identified only in individuals that were close to disease diagnosis. The lack of

significant findings in this study is most likely because we included all prodromal individuals in our dataset and did not stratify our analysis by estimated time to onset. Please note that all models showed a significant association with the covariate CAP score which reflects disease burden. Future research should avoid clumping all premanifest together into one group and should more carefully separate stages of premanifest HD.

The lack of significant findings in the psychiatric symptom data could indicate that the psychological profile of prHD may have functional or metabolic neural correlates, or may be externally driven. Although researchers have identified clinical symptoms that relate to aberrant activation of specific brain regions within prHD, this activation may not be directly affected by striatum atrophy (Klöppel et al., 2010). The psychiatric cluster score includes a wide variety of symptoms ranging from depression to obsessive tendencies, to indices of psychiatric symptom severity and distress. Perhaps these symptoms may cancel each other out such that an individual who is very apathetic may not report high distress from these symptoms. The lack of significant findings in this analysis within the psychiatric cluster warrants an investigation into specific symptoms and their underlying neural correlates. It is possible that some aspects of the psychiatric profile of this population may not be a direct result of disease atrophy, and could be treated through psychiatric pharmacotherapy to provide homeostasis to circuitry dysfunction.

Our large sample size is a strength of this study. It lends to the validity and the applicability of our cluster scores for uses in future research with this population. A limitation of this study is that the only relationships we can investigate with these measures would be related to structural atrophy. No inferences can be made regarding brain function. However, after finding that our cluster scores show similar relationships between brain volumes to those previously published, we support the utilization of cluster scores in future research with this population. Our cluster analyses subsumes previous factor analysis results published with a similar dataset, and extends our earlier factor analysis with other symptoms in the HD clinical phenotype important in the clinical care and future research investigations in this disease.

This study identified clinical domains that are related to changes in grey matter volume in a prodromal HD population. Using the largest sample size to date to analyze broad clinical domains, it appears there are three primary clusters that relate to specific subcortical changes in the prodromal population: neuropsychological measures of cognitive control, clinician ratings of motor control and standardized list learning assessments of verbal learning. Understanding the clinical changes associated with atrophy or other structural change has potential for developing a standardized set of measure for clinical trials. While previous studies have advanced our understanding of cognition in HD, few have performed such an analysis on such an extensive dataset covering multiple cognitive, motor, psychiatric, and functional domains in an attempt to reduce the amount of variables used for analysis, while at the same time retaining unique information from each measure of the HD clinical phenoptype.

### **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments

This project was supported by 5U01NS082074 (V.D. Calhoun and J.A. Turner, co-PIs) from the National Institutes of Health, National Institute of Neurological Disorders and Stroke. The PREDICT-HD study was supported by NIH/NINDS grant 5R01NS040068 awarded to Jane S. Paulsen; CHDI Foundation, Inc., A3917 and 6266 awarded to Jane S. Paulsen; Cognitive and Functional Brain Changes in Preclinical Huntington Disease (HD) 5R01NS054893 awarded to Jane S. Paulsen. We thank the PREDICT-HD sites, the study participants, the National Research Roster for Huntington's Disease Patients and Families, the Huntington's Disease Society of America and the Huntington's Study Group.

The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

### References

- Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends In Neurosciences. 1990; 13(7):266–271. [PubMed: 1695401]
- Aylward EH, Harrington DL, Mills JA, Nopoulos PC, Ross CA, Long JD. the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Regional Atrophy Associated with Cognitive and Motor Function in Prodromal Huntington Disease. Journal of Huntington's Disease. 2013; 2(4):477–489. https://doi.org/10.3233/JHD-130076.
- Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, Paulsen JS. Striatal Volume Contributes to the Prediction of Onset of Huntington Disease in Incident Cases. Biol Psychiatry. 2011; 71(9):822–828. https://doi.org/10.1016/j.biopsych.2011.07.030. [PubMed: 21907324]
- Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA. Coordinators of Huntington Study, G. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011; 82(4):405–410. https://doi.org/10.1136/jnnp. 2010.208264. [PubMed: 20884680]
- Dalley JW, Everitt BJ, Robbins TW. Impulsivity, Compulsivity, and Top-Down Cognitive Control. Neuron. 2011; 69(4):680–694. https://doi.org/http://dx.doi.org/10.1016/j.neuron.2011.01.020. [PubMed: 21338879]
- Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Predict, H. D. I. of the H. S. G. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007; 62(12):1341–1346. https://doi.org/10.1016/j.biopsych.2006.11.034. [PubMed: 17481592]
- Elliott R. Executive functions and their disorders: Imaging in clinical neuroscience. British Medical Bulletin. 2003; 65(1):49–59. https://doi.org/10.1093/bmb/65.1.49. [PubMed: 12697616]
- Epping EA, Kim J-I, Craufurd D, Brashers-Krug TM, Anderson KE, McCusker E, Paulsen J. Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data. American Journal of Psychiatry. 2015; 173(2):184–192. https://doi.org/10.1176/appi.ajp. 2015.14121551. [PubMed: 26472629]
- Epping, Ea, Mills, Ja, Beglinger, LJ., Fiedorowicz, JG., Craufurd, D., Smith, MM., Paulsen, JS. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. Journal of Psychiatric Research. 2013; 47(10):1423–1431. https:// doi.org/10.1016/j.jpsychires.2013.05.026. [PubMed: 23790259]
- Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. Journal of Neurology, Neurosurgery & Psychiatry. 2013; 84(10):1156–1160. https://doi.org/10.1136/jnnp-2012-304636.
- Fennema-Notestine C, Gamst AC, Quinn BT, Pacheco J, Jernigan TL, Thal L, Gollub RL. Feasibility of Multi-site Clinical Structural Neuroimaging Studies of Aging Using Legacy Data.

Neuroinformatics. 2007; 5(4):235–245. https://doi.org/10.1007/s12021-007-9003-9. [PubMed: 17999200]

- Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Movement Disorders: Official Journal Of The Movement Disorder Society. 2014; 29(1):105–114. https://doi.org/10.1002/mds.25717. [PubMed: 24151181]
- Ghayoor A, Vaidya JG, Johnson HJ. Development of a novel constellation based landmark detection algorithm. 2013; 8669:86693F–86693F–6.
- Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, McCusker E. Regional Specificity of Brain Atrophy in Huntington's Disease. Experimental Neurology. 1998; 154(2):663–672. https://doi.org/10.1006/exnr.1998.6919. [PubMed: 9878201]
- Harrington DL, Liu D, Smith MM, Mills Ja, Long JD, Aylward EH, Paulsen JS. Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease. Brain and Behavior. 2014; 4(1):29–40. https://doi.org/10.1002/brb3.185. [PubMed: 24653952]
- Harrington DL, Liu D, Smith MM, Mills JA, Long JD, Aylward EH, Paulsen JS. Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease. Brain Behav. 2014; 4(1):29– 40. https://doi.org/10.1002/brb3.185. [PubMed: 24653952]
- Harrington DL, Rubinov M, Durgerian S, Mourany L, Reece C, Koenig K, Rao SM. Network topology and functional connectivity disturbances precede the onset of Huntington's disease. Brain. 2015; 138(8):2332–2346. https://doi.org/10.1093/brain/awv145. [PubMed: 26059655]
- Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS. Group, the P.-H. I. and C. of the H. S. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. Journal of Neurology, Neurosurgery & Psychiatry. 2012; 83(6):612–619. https://doi.org/10.1136/jnnp-2011-301732.
- Jech R, Klempir J, Vymazal J, Zidovska J, Klempirova O, Ruzicka E, Roth J. Variation of selective gray and white matter atrophy in Huntington's disease. Mov Disord. 2007; 22(12):1783–1789. https://doi.org/10.1002/mds.21620. [PubMed: 17579363]
- Joost, MH., Raymund, CHVO., Leenders, KL., Spikman, JM. Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease, 1387–1397. 2014. https://doi.org/ 10.1007/s00415-014-7350-7
- Jovicich J, Czanner S, Han X, Salat D, van der Kouwe A, Quinn B, Fischl B. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. NeuroImage. 2009; 46(1):177–192. https://doi.org/10.1016/j.neuroimage.2009.02.010. [PubMed: 19233293]
- Julien CL, Thompson JC, Wild S, Yardumian P, Snowden JS, Turner G, Craufurd D. Psychiatric disorders in preclinical Huntington's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2007; 78(9):939–943. https://doi.org/10.1136/jnnp.2006.103309.
- Kim EY, Magnotta VA, Liu D, Johnson HJ. Stable Atlas-based Mapped Prior (STAMP) machinelearning segmentation for multicenter large-scale MRI data. Magnetic Resonance Imaging. 2014; 32(7):832–844. https://doi.org/http://dx.doi.org/10.1016/j.mri.2014.04.016. [PubMed: 24818817]
- Kloppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS. Group, P.-H. I. of the H. S. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology. 2009; 72(5):426–431. https://doi.org/10.1212/01.wnl.0000341768.28646.b6. [PubMed: 19188573]
- Klöppel S, Stonnington CM, Petrovic P, Mobbs D, Tüscher O, Craufurd D, Frackowiak RS. Irritability in pre-clinical Huntington's disease. Neuropsychologia. 2010; 48(2):549–557. https://doi.org/ 10.1016/j.neuropsychologia.2009.10.016. [PubMed: 19878688]
- Koenig KA, Lowe MJ, Harrington DL, Lin J, Durgerian S, Mourany L, Rao SM. Functional Connectivity of Primary Motor Cortex Is Dependent on Genetic Burden in Prodromal Huntington Disease. Brain Connectivity. 2014; 4(7):535–546. https://doi.org/10.1089/brain.2014.0271. [PubMed: 25072408]
- Leisman G, Braun-Benjamin O, Melillo R. Cognitive-motor interactions of the basal ganglia in development. Frontiers in Systems Neuroscience. 2014; 8:16. https://doi.org/10.3389/fnsys. 2014.00016. [PubMed: 24592214]

- Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Litvan I. Apathy is not depression. The Journal of Neuropsychiatry and Clinical Neurosciences. 1998; 10(3):314–319. [PubMed: 9706539]
- Litvan I, Paulsen JS, Mega MS, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Archives of Neurology. 1998; 55(10):1313– 1319. https://doi.org/10.1001/archneur.55.10.1313. [PubMed: 9779658]
- Malejko K, Weydt P, Sussmuth SD, Gron G, Landwehrmeyer BG, Abler B. Prodromal huntington disease as a model for functional compensation of early neurodegeneration. PLoS One. 2014; 9(12):e114569. https://doi.org/10.1371/journal.pone.0114569. [PubMed: 25541992]
- Marin, RS. The Journal of Neuropsychiatry and Clinical Neurosciences. US: American Psychiatric Assn; 1991. Apathy: A neuropsychiatric syndrome.
- Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Kulisevsky J. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. Parkinsonism & Related Disorders. 2016; 25:58–64. https://doi.org/ 10.1016/j.parkreldis.2016.02.008. [PubMed: 26898966]
- Meyer A, Zimmermann R, Gschwandtner U, Hatz F, Bousleiman H, Schwarz N, Fuhr P. Apathy in Parkinson's disease is related to executive function, gender and age but not to depression. Frontiers in Aging Neuroscience. 2014; 6:350. https://doi.org/10.3389/fnagi.2014.00350. [PubMed: 25642187]
- Moorhead TWJ, Gountouna V-E, Job DE, McIntosh AM, Romaniuk L, Lymer GKS, Lawrie SM. Prospective multi-centre Voxel Based Morphometry study employing scanner specific segmentations: procedure development using CaliBrain structural MRI data. BMC Medical Imaging. 2009; 9(1):8. https://doi.org/10.1186/1471-2342-9-8. [PubMed: 19445668]
- Naarding P, Janzing JGE, Eling P, van der Werf S, Kremer B. Apathy is not depression in Huntington's disease. The Journal of Neuropsychiatry and Clinical Neurosciences. 2009; 21(3):266–270. https:// doi.org/10.1176/appi.neuropsych.21.3.266. [PubMed: 19776305]
- O'Rourke JJ, Beglinger LJ, Smith MM, Mills J, Moser DJ, Rowe KC. the PREDICT-HD Investigators of the Huntington Study Group. The Trail Making Test in Prodromal Huntington Disease: Contributions of Disease Progression to Test Performance. Journal of Clinical and Experimental Neuropsychology. 2011; 33(5):567–579. https://doi.org/10.1080/13803395.2010.541228. [PubMed: 21302170]
- Papp KV, Snyder PJ, Mills JA, Duff K, Westervelt HJ, Long JD, Paulsen JS. Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease. Arch Clin Neuropsychol. 2013; 28(2):156–168. https://doi.org/ 10.1093/arclin/acs105. [PubMed: 23246934]
- Naarding, Paul, PhDMD, Janzing, GE., PhDMD, Eling, Paul, PD, van der Werf, Sieberen, PD, Kremer, Berry, PhDMD. Apathy Is Not Depression in Huntington's Disease. The Journal of Neuropsychiatry and Clinical Neurosciences. 2009; 21(3):266–270. https://doi.org/doi:10.1176/ jnp.2009.21.3.266. [PubMed: 19776305]
- Paulsen JS. Early Detection of Huntington Disease. Future Neurology. 2010; 5(1) https://doi.org/ 10.2217/fnl.09.78. doi: 10.2217/fnl.09.78
- Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross Ca, Nance M, Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery, and Psychiatry. 2008a; 79(8):874–880. https://doi.org/10.1136/jnnp.2007.128728.
- Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross Ca, Nance M, Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery, and Psychiatry. 2008b; 79(8):874–880. https://doi.org/10.1136/jnnp.2007.128728.
- Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK. Coordinators of the Huntington Study, G. Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. Front Aging Neurosci. 2014; 6:78. https:// doi.org/10.3389/fnagi.2014.00078. [PubMed: 24795630]
- Paulsen JS, Long JD, Ross CA, Harrington DL, Erwin CJ, Williams JK, Barker RA. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. The Lancet Neurology. 2014; 13(12):1193–1201. https://doi.org/10.1016/ s1474-4422(14)70238-8. [PubMed: 25453459]

- Paulsen JS, Magnotta Va, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC. Brain structure in preclinical Huntington's disease. Biological Psychiatry. 2006; 59(1):57–63. https:// doi.org/10.1016/j.biopsych.2005.06.003. [PubMed: 16112655]
- Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Nance M. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010; 82(3– 4):201–207. https://doi.org/10.1016/j.brainresbull.2010.04.003. [PubMed: 20385209]
- Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Shoulson I. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 2001; 57(4):658–662. [PubMed: 11524475]
- Pla P, Orvoen S, Saudou F, David DJ, Humbert S. Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms. Frontiers in Behavioral Neuroscience. 2014; 8:135. https://doi.org/10.3389/fnbeh.2014.00135. [PubMed: 24795586]
- R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015. Retrieved from http://www.R-project.org/
- Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. Movement Disorders. 2014; 29(11):1335–1341. https://doi.org/10.1002/mds.26011. [PubMed: 25164527]
- Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurology. 2011; 10(1):83–98. https://doi.org/10.1016/S1474-4422(10)70245-3. [PubMed: 21163446]
- Snowden JS, Craufurd D, Thompson J, Neary D. Psychomotor, Executive, and Memory Function in Preclinical Huntington'sDisease. Journal of Clinical & Experimental Neuropsychology. 2002; 24(2):133. [PubMed: 11992196]
- Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Aylward EH. Neurocognitive signs in prodromal Huntington disease. Neuropsychology. 2011; 25(1):1–14. https://doi.org/10.1037/a0020937. [PubMed: 20919768]
- Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Stout JC. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12month longitudinal analysis. The Lancet Neurology. 2011; 10(1):31–42. https://doi.org/10.1016/ s1474-4422(10)70276-3. [PubMed: 21130037]
- Unschuld PG, Joel SE, Liu X, Shanahan M, Margolis RL, Biglan KM, Ross Ca. Impaired corticostriatal functional connectivity in prodromal Huntington's Disease. Neuroscience Letters. 2012; 514(2):204–209. https://doi.org/10.1016/j.neulet.2012.02.095. [PubMed: 22425717]
- Vaccarino AL, Sills T, Anderson KE, Bachoud-Levi AC, Borowsky B, Craufurd D, Evans K. Assessment of depression, anxiety and apathy in prodromal and early huntington disease. PLoS Curr. 2011a; 3:RRN1242. https://doi.org/10.1371/currents.RRN1242. [PubMed: 21731882]
- Vaccarino AL, Sills T, Anderson KE, Bachoud-Levi AC, Borowsky B, Craufurd D, Evans K. Assessment of depression, anxiety and apathy in prodromal and early huntington disease. PLoS Curr. 2011b; 3:RRN1242. https://doi.org/10.1371/currents.RRN1242. [PubMed: 21731882]
- van den Bogaard SJA, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI. Group, T.-H. I. Early atrophy of pallidum and accumbens nucleus in Huntington's disease. Journal of Neurology. 2011; 258(3):412–420. https://doi.org/10.1007/s00415-010-5768-0. [PubMed: 20936300]
- Verbeke, G., Molenberghs, G. Linear mixed models for longitudinal data. New York: Springer; 2000.
- Walker FO. Huntington's disease. The Lancet. 369(9557):218–228. (20). https://doi.org/10.1016/ S0140-6736(07)60111-1.
- Whalley CH, Wardlaw MJ. Accuracy and reproducibility of simple cross-sectional linear and area measurements of brain structures and their comparison with volume measurements. Neuroradiology. 2001; 43(4):263–271. https://doi.org/10.1007/s002340000437. [PubMed: 11338407]
- Williams JK, Kim J-I, Downing N, Farias S, Harrington DL, Long JD, Paulsen JS. Everyday cognition in prodromal Huntington disease. Neuropsychology. 2015; 29(2):255–267. https://doi.org/10.1037/ neu0000102. [PubMed: 25000321]

- Wolf RC, Thomann PA, Thomann AK, Vasic N, Wolf ND, Landwehrmeyer GB, Orth M. Brain Structure in Preclinical Huntington's Disease: A Multi-Method Approach. Neurodegenerative Diseases. 2013; 12(1):13–22. [PubMed: 22906775]
- Young Kim E, Johnson HJ. Robust multi-site MR data processing: iterative optimization of bias correction, tissue classification, and registration. Frontiers in Neuroinformatics. 2013; 7:29. https:// doi.org/10.3389/fninf.2013.00029. [PubMed: 24302911]
- Zhang Y, Long JD, Mills JA, Warner JH, Lu W, Paulsen JS. Group, the P.-H. I. of the H. S. Indexing Disease Progression at Study Entry with Individuals At-Risk for Huntington Disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : The Official Publication of the International Society of Psychiatric Genetics. 2011; 156(7):751–763. https://doi.org/10.1002/ ajmg.b.31232.



#### Figure 1.

Results from the hierarchical cluster analysis. Interpretation of the clusters is conducted using the cut-off point as well as the distance shown between each classification dissection. For instance the first three subdivisions are more robust than the next four using distance parameters

legend: Blue line depicts our cut point, and red line indicates our cluster score groups. Bold lettering on the left depicts the name of the cluster, and in smaller text are the names of individual measures used to calculate each cluster score.



### Figure 2.

Motor Symptom cluster scores and caudate volumes(B=-1, t(936)=-2.74, p=.02) Legend: Blue line indicates regression line of best fit, grey dots are data points.



# Putamen volumes (as a percentage of intracranial volume)

#### Figure 3.

Motor Symptom cluster scores and putamen volumes (B=-1.07, t(936)=-2.36, p=.04) Legend: Blue line indicates regression line of best fit, grey dots are data points.



Globus Pallidus volumes (as a percentage of intracranial volume)

### Figure 4.

Cognitive control cluster scores and Globus Pallidus volumes. (B=1.42, t(904)=1.17, p=. 03).

Legend: Blue line indicates regression line of best fit, grey dots are data points.



Putamen volumes (as a percentage of intracranial volume)

### Figure 5.

Cognitive control cluster scores and putamen volumes. (B=1.31, t(904)=2.59, p=.02) Legend: Blue line indicates regression line of best fit, grey dots are data points.



# Nucleus Accumbens Volumes (as a percentage of intracranial volume)

### Figure 6.

Cognitive control cluster scores and nucleus accumbens volumes. (B=1.22, t(904)=2.52, p=. 02)

Legend: Blue line indicates regression line of best fit, grey dots are data points.



Caudate Volumes (as a percentage of intracranial volume)

#### Figure 7.

Verbal Learning subcluster scores and caudate volumes. (B=1.99, t(664)=3.07, p=.005) Clustering and factor analysis are often used for the same purpose: to find homogenous subset of variables, i.e., to find clusters. Clustering has the advantage in my mind of forcing variables into unambiguous clusters, whereas factor analysis does not do so and a variable can have similar loadings on many factors. Ji-in did a thorough job in investigating the variables at baseline, but we never published a paper. I think this would be great for you to do for a paper, at least as a preliminary analysis step.

Legend: Blue line indicates regression line of best fit, grey dots are data points.

Participant characteristics for the cluster and regression analyses.

Demographic Variable	Mean (SD)
Sex (M/F)	360/624
Age	41.87 (11.08)
Years of Education	14.46 (2.6)
CAG Repeat Length	42.49 (2.06)
CAP Score	353.53 (87.99)

Note. N =984, M/F= Male/Female, SD= Standard Deviation.

Motor Symptom Cluster Score Mixed Effects Model.

Fixed Effects	В	Std. Error	t Score	Effect Size
1. Intercept	0.59	0.31	1.93	1.90
2. Caudate	-1.00	0.37	-2.74*	-2.70
3. Putamen	-1.07	0.46	-2.36*	-2.33
4. Accumbens	-6.44	4.52	-1.43	-1.42
5. Globus Pallidus	0.54	1.13	0.48	0.48
6. Thalamus	0.54	0.32	1.66	1.69
7. Cap Score	0.14	0.03	5.34*	4.67
8. Sex	-0.05	0.04	-1.20	-1.25
9. Years of Education	-0.03	0.02	-1.53	-1.50

*N*= 568,

\* = *p*<.05.

CAP scores were positively related to motor symptom scores (B=.14, t(936)= 5.34, p<.01), i.e. individuals with greater CAP scores showed more severe symptoms.

Cognitive Control Cluster Score Mixed Effects Model.

Fixed Effects	В	Std. Error	t Score	Effect Size
1. Intercept	-1.32	0.34	-3.83	-3.88
2. Caudate	0.25	0.41	0.60	0.61
3. Putamen	1.31	0.51	2.59 **	2.57
4. Accumbens	12.20	4.84	2.52**	2.52
5. Globus Pallidus	1.42	1.22	1.17**	1.16
6. Thalamus	-0.03	0.37	-0.09	-0.08
7. CAP Score	-0.20	0.03	-6.72**	-6.67
8. Gender	-0.03	0.05	-0.60	-0.6
9. Years of Education	0.20	0.02	8.80**	10

*N*= 905,

\* = *p*<.05,

 $^{**}_{= p .01.}$ 

Both CAP score (B=-0.20, t(904)=-6.72, p<.01) and years of education (B=.2, t(904)=8.80, p<.01) were significantly related to cognitive control cluster scores.

Verbal Learning subcluster Mixed Effects Model.

Fixed Effects	В	Std. Error	t score	Effect Size
1. Intercept	-1.52	0.52	0.66	-2.92
2. Caudate	1.99	0.65	3.07**	3.06
3. Putamen	0.52	0.83	0.63	0.63
4. Accumbens	1.57	8.10	0.19	0.19
5. Globus Pallidus	0.21	2.31	0.09	0.09
6. Thalamus	-1.44	0.56	-2.55	-2.57
7. CAP Score	-0.22	0.04	-4.19**	-5.50
8. Gender	0.23	0.07	-3.19**	3.29
9. Years of Education	0.18	0.03	5.39 **	6.00

*N*= 666,

\* = *p*<.05,

Years of education were significantly related to verbal learning subcluster scores, (B=0.18, t(665)= 5.39, p<.01). CAP score was significantly related to verbal learning subcluster scores, (B=-0.22, t(665)=-4.19, p<.01). Gender was significantly related to verbal learning subcluster scores, with women outperforming men (B=0.23, t(665)=-3.19, p<.01).

 $<sup>^{**}</sup>_{= p}$  .01.